Date
Attendees
| Committee Member | Present | Absent |
|---|---|---|
| X | ||
| Amy Leblanc | X | |
| X | ||
| X | ||
X | ||
| Debbie Knapp | X | |
| Toby Hecht | X | |
| Ralph Parchment | X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
- Debbie to write invitation for Jaime Modiano
- Revisit new steering committee members in September
- Debbie Knapp to send an email to FidoCure and Vidium to see if these groups are willing to sit down and meet with us.
Agenda
| Item | Who | Talking Points |
|---|---|---|
| Discussion of potential submission of FidoCure Animal Health data |
| |
| New article from Purdue Office of Research | Debbie Knapp | |
| DGAB Updates | New Data Submission Request
Recently Approved
ICDC Studies in Active Submission
| |
| BPSC Updates |
| |
| Upcoming Steering Committee Meeting | Ralph Parchment |
|
| 2023 Q2 Software Release |
|
Minutes (Not Verbatim)
AL - Lets get the data they have (my understanding is they conduct hotspot panels primarily from FFPE samples), lets get the genomic files, the demographic data and the histological or cytological data. If they have treatment and outcome data that would be valuable. This data would only be useful if we have these dimensions. Some data may come from dogs that were immediately euthanized or treated through palliative care.
TH - We may want to focus on specific malignancies and perhaps cases to augment osteosarcoma and bladder cancer. We could tell them the cancer types we are specifically interested in.
AL - A good example would be mast cell tumors, there would be value in them even though they are most prevalent in canine, but could serve researchers interested in KIT. Maybe they could send us a rough manifest of the type of histological canine cases they have to serve as a starting point.
TH - Or we can give them a list of histologies that we are interested in along with anything that has commonalities with human. We have to figure out what is the best thing for us to do since there will be an associated cost.
AL - We need to find out what specifically is on the hotspot panel
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Action items
- Kuffel, Gina (NIH/NCI) [C] to relay info to Debbie for cancer types of interest to request from FidoCure: Glioma, osteosarcoma, bladder cancer, mucosal and acral melanoma, mast cell tumor. Request overview of what they have in their DB.
